AXL and glioblastoma: Liu and colleagues investigated the effects of intracranial administration of (Z)-n-butylidenephthalide [(Z)-BP], released via Cerebraca Wafers (CWs), in combination with TMZ to target AXL and mTOR in the glioblastoma framework [96].